Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Vera Therapeutics (Nasdaq: VERA) announced inducement awards granted to seven new employees on November 4, 2024. The awards include non-qualified stock options to purchase 54,050 shares of Class A common stock at $45.17 per share and restricted stock units (RSUs) for 27,025 shares. The stock options will vest over four years, with 25% vesting after one year and the remainder monthly over 36 months. The RSUs will vest 25% annually over four years starting November 20, 2024. These grants were approved under Nasdaq Listing Rule 5635(c)(4) as employment inducements.
Vera Therapeutics (Nasdaq: VERA) ha annunciato premi per inducimento concessi a sette nuovi dipendenti il 4 novembre 2024. I premi includono opzioni su azioni non qualificate per l'acquisto di 54.050 azioni di azioni ordinarie di Classe A al prezzo di $45,17 per azione e unità di azioni vincolate (RSU) per 27.025 azioni. Le opzioni su azioni matureranno nell'arco di quattro anni, con il 25% che matura dopo un anno e il restante mensilmente per 36 mesi. Le RSU matureranno il 25% annualmente nel corso di quattro anni a partire dal 20 novembre 2024. Questi premi sono stati approvati ai sensi della Regola di Quotazione Nasdaq 5635(c)(4) come inducimenti per l'occupazione.
Vera Therapeutics (Nasdaq: VERA) anunció premios de inducción otorgados a siete nuevos empleados el 4 de noviembre de 2024. Los premios incluyen opciones de acciones no calificadas para comprar 54,050 acciones comunes de Clase A a $45.17 por acción y unidades de acciones restringidas (RSUs) para 27,025 acciones. Las opciones sobre acciones se otorgarán durante un período de cuatro años, con un 25% disponible después de un año y el resto mensualmente durante 36 meses. Las RSUs se otorgarán anualmente en un 25% durante cuatro años a partir del 20 de noviembre de 2024. Estas concesiones fueron aprobadas bajo la Regla de Cotización Nasdaq 5635(c)(4) como inducimientos para el empleo.
베라 테라퓨틱스 (Nasdaq: VERA)는 2024년 11월 4일에 7명의 새로운 직원에게 제공된 유인 보상을 발표했습니다. 이 보상에는 비정규 주식 옵션이 포함되어 있으며, 주식 A 클래스의 일반주 54,050주를 주당 $45.17에 구매할 수 있고, 제한 가주식 단위(RSU)가 27,025주에 대한 것입니다. 주식 옵션은 4년에 걸쳐 매년 25%씩 36개월 동안 매달 베스팅되며, RSU는 2024년 11월 20일부터 시작하여 4년에 걸쳐 연간 25%씩 베스팅됩니다. 이러한 보상은 직원 유인을 위한 Nasdaq 상장 규칙 5635(c)(4)에 따라 승인되었습니다.
Vera Therapeutics (Nasdaq: VERA) a annoncé des primes d'incitation accordées à sept nouveaux employés le 4 novembre 2024. Ces primes comprennent des options d'achat d'actions non qualifiées permettant d'acheter 54 050 actions ordinaires de Classe A au prix de 45,17 $ par action et des unités d'actions restreintes (RSU) représentant 27 025 actions. Les options d'achat d'actions acquerront leurs droits sur une période de quatre ans, avec 25 % devenant acquises après un an et le reste mensuellement sur 36 mois. Les RSU acquerront leurs droits annuellement à hauteur de 25 % sur quatre ans à partir du 20 novembre 2024. Ces attributions ont été approuvées conformément à la règle d'inscription Nasdaq 5635(c)(4) comme incitations à l'emploi.
Vera Therapeutics (Nasdaq: VERA) hat am 4. November 2024 Anreizprämien für sieben neue Mitarbeiter bekannt gegeben. Die Prämien umfassen nicht qualifizierte Aktienoptionen zum Kauf von 54.050 Aktien der Klasse A zum Preis von 45,17 $ pro Aktie sowie eingeschränkte Aktieneinheiten (RSUs) für 27.025 Aktien. Die Aktienoptionen werden über einen Zeitraum von vier Jahren fällig, wobei 25 % nach einem Jahr und der Rest monatlich über 36 Monate fällig wird. Die RSUs werden jährlich über einen Zeitraum von vier Jahren ab dem 20. November 2024 fällig. Diese Zuwendungen wurden gemäß der Nasdaq-Listing-Regel 5635(c)(4) als Anreize für die Beschäftigung genehmigt.
- Expansion of workforce with seven new employees
- Stock price of $45.17 per share used as exercise price indicates strong market valuation
- Potential dilution of existing shareholders through new stock options and RSUs
Brisbane, Calif., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that on November 4, 2024, the Compensation Committee granted inducement awards consisting of a non-qualified stock option to purchase 54,050 shares of Class A common stock and restricted stock units (RSUs) for 27,025 shares of Class A common stock to seven new employees under the Inducement Plan. The Compensation Committee approved the awards as an inducement material to the new employees’ employment in accordance with Nasdaq Listing Rule 5635(c)(4).
The stock option granted on November 4, 2024 has an exercise price per share equal to
About Vera
Vera Therapeutics is a late clinical-stage biotechnology company focused on developing treatments for serious immunological diseases. Vera’s mission is to advance treatments that target the source of immunological diseases in order to change the standard of care for patients. Vera’s lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B-cell Activating Factor (BAFF) and A PRoliferation-Inducing Ligand (APRIL), which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases, including IgAN, also known as Berger’s disease, and lupus nephritis. In addition, Vera is evaluating additional diseases where the reduction of autoantibodies by atacicept may prove medically useful. Vera is also developing MAU868, a monoclonal antibody designed to neutralize infection with BK virus (BKV), a polyomavirus that can have devastating consequences in certain settings such as kidney transplant. Vera retains all global developmental and commercial rights to atacicept and MAU868. For more information, please visit www.veratx.com.
For more information, please contact:
Investor Contact:
Joyce Allaire
LifeSci Advisors
212-915-2569
jallaire@lifesciadvisors.com
Media Contact:
Madelin Hawtin
LifeSci Communications
MHawtin@lifescicomms.com
FAQ
How many shares were granted in Vera Therapeutics' (VERA) November 2024 inducement awards?
What is the exercise price for VERA's November 2024 stock option grants?
What is the vesting schedule for VERA's November 2024 inducement RSUs?
